SCHEDULE: Millennium Funds Disclose Nektar Therapeutics Stake
Beneficial Ownership Report
Millennium Management LLC and affiliated entities have disclosed a 3.0% passive beneficial ownership stake in Nektar Therapeutics common stock as of September 30, 2025.
Summary
- Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander collectively beneficially own 570,994 shares of Nektar Therapeutics common stock.
- This collective ownership represents 3.0% of the class of Nektar Therapeutics' common stock.
- Integrated Core Strategies (US) LLC, an affiliate, beneficially owns 333,576 shares, representing 1.8% of the class.
- All reporting persons have shared voting and shared dispositive power over their respective reported holdings.
- The securities were not acquired and are not held for the purpose of changing or influencing the control of Nektar Therapeutics.
Sentiment
Score: 5
Explanation: The filing is a neutral disclosure of passive beneficial ownership by institutional investors and does not contain information that would inherently indicate positive or negative sentiment regarding the issuer's performance or outlook.
Industry Context
This filing reflects a significant institutional investor's passive stake in Nektar Therapeutics, a biotechnology company. Such disclosures are common in the biotech sector, where institutional interest can signal confidence or strategic positioning in companies with pipeline developments.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Ownership Disclosure | The filing explicitly states that the securities were not acquired and are not held for the purpose of changing or influencing the control of the issuer, aligning with passive investment regulations. | 09/30/2025 | Reinforces the passive nature of the investment, indicating no immediate intent for activist engagement or corporate governance changes by the reporting parties. |
Stakeholder Impact
- Shareholders: Disclosure of significant institutional ownership can influence market perception and potentially investor confidence.
- Company Management: Awareness of a significant passive institutional stake may be noted, but without activist intent, direct impact is limited.
Key Dates
| Date | Description |
|---|---|
| 09/30/2025 | Date of event which required the filing of this statement |
| 10/27/2025 | Filing date of the Schedule 13G Amendment No. 1 |
| 10/27/2025 | Date of Joint Filing Agreement |
Keywords
Nektar Therapeutics, NKTR, Millennium Management, Integrated Core Strategies, Israel A. Englander, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Investor
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.